Effects of allopurinol in Duchenne's muscular dystrophy.
There is no effective treatment at present for Duchenne's muscular dystrophy (DMD). Recently, clinical improvement and increased muscle strength have been reported after 100 mg of allopurinol was administered daily to 21 boys with DMD in a double-blind crossover study. Its effectiveness was determined by an extensive battery of muscle function, cardiac, and laboratory tests. The ten-month study was divided into four periods; (1) one month of baseline observation; (2) three months of therapy to allopurinol and placebo control groups; (3) three months of therapy to crossed over groups; and (4) three months of therapy to all patients. No statistically significant changes between the allopurinol and control periods occurred in the muscle function tests. The earlier report of clinical improvement during allopurinol treatment was not confirmed.
D000293:Adolescent; D000493:Allopurinol / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004562:Electrocardiography; D006801:Humans; D008297:Male; D009132:Muscles / Q000503:physiopathology; D009136:Muscular Dystrophies / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos
D010919:Placebos; D000493:Allopurinol